# Semaglutide and Vascular Regeneration

Study · id `cardio:ct-nct05870462` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05870462](<https://clinicaltrials.gov/study/NCT05870462>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05870462

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05870462. Randomized; no masking; primary purpose basic science. Start 2023-04-29 (actual); primary completion 2024-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05870462, source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)
- Started: 2023-04-29 (actual) (ClinicalTrials.gov record NCT05870462, source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)
- Primary completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05870462, source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05870462, source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05870462, source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05870462-2023-07-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide and Vascular Regeneration
- Acronym: SEMA-VR
- Condition: Atherosclerosis
- Condition: Cardiovascular Diseases
- Condition: Diabetes Mellitus, Type 2
- Condition: Obesity
- Intervention (Drug): Semaglutide Pen Injector
- Lead sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
- Lead sponsor class: OTHER
- Collaborator: Unity Health Toronto
- Collaborator class: OTHER
- Collaborator: Western University, Canada
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Unity Health Toronto (`cardio:org-unity-health-toronto`)

## Provenance

Content hash: 0f80ea7bf9b29248236fcad995f1ef6351de12a2fcfd3d15e07395f11e13c8b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
